2. Academic Validation
  3. Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors

  • J Med Chem. 2017 May 11;60(9):4023-4035. doi: 10.1021/acs.jmedchem.7b00357.
Miao Zhan 1,  Yufang Deng 1,  Lifeng Zhao 2,  Guoyi Yan 1,  Fangying Wang 1,  Ye Tian 1,  Lanxi Zhang 1,  Hongxia Jiang 1,  Yuanwei Chen 1 3
Affiliations

Affiliations

  • 1 State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China.
  • 2 Sichuan Industrial Institute of Antibiotics, Chengdu University , Chengdu 610052, China.
  • 3 Hinova Pharmaceuticals Inc. , Suite 402, Building B, #5 South KeYuan Road, Chengdu, 610041, China.
PMID: 28409639 DOI: 10.1021/acs.jmedchem.7b00357
Abstract

Dysfunctional signaling of the PI3K/Akt/mTOR pathway in Cancer and its crucial role in cell growth and survival have made it a much desired target for Cancer therapeutics. A series of dimorpholine substituted thienopyrimidine derivatives had been prepared and evaluated in vitro and in vivo. Among them, compound 14o was identified as a dual Class I PI3K and mTOR kinase inhibitor, which had an approximately 8-fold improvement in mTOR inhibition relative to the class I PI3K Inhibitor 1 (pictilisib, GDC-0941). Western blot analysis confirmed the 14o mechanistic modulation of the cellular PI3K/Akt/mTOR pathway through inhibiting phosphorylation of both Akt and S6 in human Cancer cell lines. In addition, 14o demonstrated significant efficacy in SKOV-3 and U87MG tumor xenograft models without causing significant weight loss and toxicity.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z